Wedbush Has Optimistic Outlook of Biogen Q1 Earnings

Biogen Inc. (NASDAQ:BIIB - Free Report) - Analysts at Wedbush upped their Q1 2027 earnings estimates for Biogen in a report released on Tuesday, October 14th. Wedbush analyst L. Chico now anticipates that the biotechnology company will post earnings of $4.13 per share for the quarter, up from their previous forecast of $3.85. Wedbush currently has a "Neutral" rating and a $135.00 price target on the stock. The consensus estimate for Biogen's current full-year earnings is $15.83 per share. Wedbush also issued estimates for Biogen's Q2 2027 earnings at $4.67 EPS and Q3 2027 earnings at $4.34 EPS.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $5.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.93 by $1.54. Biogen had a net margin of 15.31% and a return on equity of 13.85%. The company had revenue of $2.65 billion for the quarter, compared to analysts' expectations of $2.32 billion. During the same quarter in the previous year, the company earned $5.28 earnings per share. Biogen's quarterly revenue was up 7.3% on a year-over-year basis. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS.

BIIB has been the topic of several other research reports. Royal Bank Of Canada reduced their price target on shares of Biogen from $219.00 to $217.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 8th. HC Wainwright upped their price objective on shares of Biogen from $187.00 to $194.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Morgan Stanley upped their price objective on shares of Biogen from $144.00 to $149.00 and gave the stock an "equal weight" rating in a report on Friday, October 10th. William Blair restated an "outperform" rating on shares of Biogen in a report on Wednesday, September 24th. Finally, Truist Financial began coverage on shares of Biogen in a report on Monday, July 21st. They issued a "hold" rating and a $142.00 price objective on the stock. Eleven equities research analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Biogen presently has an average rating of "Hold" and an average price target of $180.69.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $142.26 on Friday. Biogen has a 1 year low of $110.04 and a 1 year high of $191.19. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.50 and a quick ratio of 1.79. The company's 50-day moving average is $141.29 and its 200 day moving average is $131.36. The stock has a market capitalization of $20.86 billion, a P/E ratio of 13.60, a P/E/G ratio of 1.14 and a beta of 0.13.

Insider Activity at Biogen

In other news, insider Priya Singhal sold 517 shares of the stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $133.55, for a total transaction of $69,045.35. Following the sale, the insider owned 5,772 shares in the company, valued at $770,850.60. This represents a 8.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.18% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Biogen

A number of institutional investors have recently made changes to their positions in BIIB. Norges Bank bought a new position in Biogen during the second quarter valued at approximately $284,358,000. AQR Capital Management LLC lifted its position in Biogen by 153.6% during the first quarter. AQR Capital Management LLC now owns 1,368,842 shares of the biotechnology company's stock valued at $187,258,000 after purchasing an additional 829,150 shares during the period. OVERSEA CHINESE BANKING Corp Ltd lifted its position in Biogen by 1,663.4% during the first quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 780,567 shares of the biotechnology company's stock valued at $106,813,000 after purchasing an additional 736,301 shares during the period. Orion Porfolio Solutions LLC lifted its position in Biogen by 6,828.4% during the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company's stock valued at $64,965,000 after purchasing an additional 509,809 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in Biogen by 190.7% during the second quarter. Arrowstreet Capital Limited Partnership now owns 624,371 shares of the biotechnology company's stock valued at $78,415,000 after purchasing an additional 409,591 shares during the period. Hedge funds and other institutional investors own 87.93% of the company's stock.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.